Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) benefit from innovative treatments for obesity and diabetes. Start Your ...

How Eli Lilly’s Next 5 Years Could Play Out We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong ...

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders should know. We ...

There is some expectation that Eli Lilly's pipeline will break through, and analysts are particularly optimistic about ...

The list prices of the top 25 drugs with the highest Medicare Part D spend that are not subject to drug price negotiations ...

This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...